What happened with CAH today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cardinal Health buys medicines from manufacturers and distributes them to pharmacies, hospitals and other healthcare providers in the United States. Pharmaceutical sales account for the vast majority of revenue. Customers pay for the products, while branded-drug manufacturers also compensate Cardinal Health for distribution and related services, generally based on manufacturer-set drug prices. On generic drugs, it earns margins supported by supplier discounts, rebates and service fees.
Its smaller medical-products business makes and sources Cardinal Health-brand medical, surgical and laboratory supplies and sells them to healthcare providers. It also distributes other manufacturers’ products, giving the company a business beyond medicines.
CVS Health is its largest customer and supplies a substantial share of revenue. CVS Health is also its partner in Red Oak Sourcing, which negotiates generic-drug supply contracts for both companies. Pharmaceutical earnings depend on customer purchasing volumes and contract renewals, drug prices and sourcing costs—not simply on sales growth. Its opioid settlement requires ongoing changes to programs designed to prevent controlled medicines from being diverted to improper use, placing operating obligations on its distribution business.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
McKesson competes with Cardinal Health to supply branded, generic and specialty medicines and sell services to pharmacies, hospitals and physician practices. Watch McKesson’s specialty-drug distribution and physician services for signs of competitive pressure on Cardinal Health in those same businesses.
Cencora competes with Cardinal Health for healthcare providers’ spending on wholesale medicines, specialty-drug distribution and related services. Its distribution and services for community oncologists are a concrete place to watch that rivalry.
Cardinal Health depends heavily on CVS Health’s pharmaceutical purchases: CVS was its largest customer and accounted for 28% of fiscal 2026 revenue. Watch CVS’s pharmacy purchasing and the generic supply contracts negotiated for both companies by their U.S. venture, Red Oak Sourcing, whose term extends through June 2029.
Medline Inc. competes with Cardinal Health to make and distribute medical-surgical supplies sold to hospitals, surgery centers and other healthcare providers. Watch which company wins agreements to serve as a provider’s main supplier, since both compete for those contracts.
CVS HEALTH CORPORATION earningsCVS
CVS Health’s report will show whether its pharmacy purchasing is holding up, a key source of demand for Cardinal Health’s largest customer relationship.
Look for what CVS says about pharmacy operations and drug purchasing, and read that alongside Cardinal’s disclosed share of revenue from CVS. Steady purchasing would indicate that this major customer continues to buy medicines; weaker purchasing would raise pressure on Cardinal’s demand. Red Oak handles generic sourcing for both companies, but CVS’s results alone do not show how much Cardinal earns under related contracts.
McKesson Corporation earningsMCK
McKesson’s report will show provider demand for specialty-drug distribution and related services, where it competes with Cardinal Health for the same customers.
Watch McKesson’s reported performance and commentary on specialty-drug distribution and physician services. Strength would indicate that providers are still buying these services; weakness could point to softer demand or tougher competition, either of which raises pressure on Cardinal’s corresponding business. McKesson’s figures are a market signal, not a substitute for Cardinal’s own sales and profit.
Medline Inc. earningsMDLN
Medline Inc.’s report will show provider demand for medical-surgical supplies, where it competes with Cardinal Health’s GMPD business for customers and contracts.
Look at Medline’s medical-surgical sales, customer demand and commentary on major supply agreements. Strong sales and contract activity would indicate that providers are still buying, while confirming active competition for Cardinal’s GMPD business; weakness could ease competitive pressure but may also signal softer market demand. Medline’s report does not reveal which contracts Cardinal won.
Cardinal Health, Inc. earningsThis company
Cardinal Health sells medicines to pharmacies, hospitals and other healthcare providers, and its report will show whether Pharma revenue growth is translating into segment profit.
Read Pharma revenue alongside segment profit, and note what the company says about generic-program economics and branded and specialty drug sales. If both rise, expanding sales are contributing profit; if revenue rises but profit stalls or falls, product mix, generic pricing or costs are absorbing the growth.
